MED12 and non-small cell lung carcinoma: Across the major datasets analyzed in this study (MSKCC: 3.42%, TCGA: 3.31%, our cohort: 3.39%), the proportion of NSCLC patients harboring non-synonymous MED12 mutations was consistently low, typically around 3–4%.